TesoRx and CoreRx Announce Joint Venture to Manufacture First-in-Class Oral Testosterone Drug — BioPortfolio.com

TesoRx and CoreRx Announce Joint Venture to Manufacture First-in-Class Oral Testosterone Drug — BioPortfolio.com

TesoRx Pharma, LLC and CoreRx, Inc. today announced a manufacturing joint venture to produce TSX-002, a first-in-class oral testosterone drug targeting the $2.5Billion low testosterone market. TesoRx’s novel, proprietary formulation orally delivers therapeutic levels of unmodified testosterone in a safe and convenient manner. The company will be commencing its final Phase 3 Clinical Study in Q1 of 2014. said Ramachandran “TR” Thirucote, Ph.D., CEO of TesoRx.

Read the source article at bioportfolio.com

About the Author

Leave a Reply

*